Beyond the monoamine hypothesis: Auvelity, a glutamatergic approach to treating major depressive disorde
Posted about 2 years ago by Deedra Harrington
Beyond the monoamine hypothesis:
Auvelity, a glutamatergic approach to treating major depressive disorder
Objectives:
-
To highlight the ongoing and escalating impact of MDD on patients’ lives in the United States
-
To discuss the proposed mechanism of action and clinical considerations for Auvelity, the first and only oral NMDA receptor antagonist for the treatment of MDD in adults
-
To review key data on symptom improvement, clinical response, and remission from the pivotal GEMINI trial, confirmatory ASCEND trial, and long-term safety trial COMET
Date:
8/3/2023
Time:
6:00 PM, Central Time
Location:
Ruth's Chris Steak House 620 W Pinhook Rd Lafayette, LA 70503
Presented by:
Matthew Berger, MD
Title:
Psychiatrist, Private Practice
Affiliation:
Matthew Berger, MD, PC
RSVP:
Christie Maranto at cmaranto@axsome.com or 917-596-2287